Donoghue Forlines LLC Sells 2,044 Shares of Pfizer Inc. (NYSE:PFE)

Donoghue Forlines LLC trimmed its stake in Pfizer Inc. (NYSE:PFEGet Rating) by 3.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 50,389 shares of the biopharmaceutical company’s stock after selling 2,044 shares during the quarter. Donoghue Forlines LLC’s holdings in Pfizer were worth $2,975,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of PFE. Franklin Resources Inc. boosted its stake in shares of Pfizer by 28.8% during the 3rd quarter. Franklin Resources Inc. now owns 45,980,291 shares of the biopharmaceutical company’s stock worth $1,977,614,000 after acquiring an additional 10,270,562 shares during the period. Caisse DE Depot ET Placement DU Quebec boosted its stake in shares of Pfizer by 470.3% during the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 10,012,954 shares of the biopharmaceutical company’s stock worth $430,657,000 after acquiring an additional 8,257,100 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Pfizer by 215.5% during the 3rd quarter. Renaissance Technologies LLC now owns 7,457,601 shares of the biopharmaceutical company’s stock worth $320,751,000 after acquiring an additional 5,093,860 shares during the period. Allspring Global Investments Holdings LLC bought a new position in shares of Pfizer during the 4th quarter worth approximately $262,207,000. Finally, TD Asset Management Inc. boosted its stake in shares of Pfizer by 116.0% during the 4th quarter. TD Asset Management Inc. now owns 7,806,890 shares of the biopharmaceutical company’s stock worth $460,997,000 after acquiring an additional 4,192,157 shares during the period. Hedge funds and other institutional investors own 66.50% of the company’s stock.

In other Pfizer news, SVP Jennifer B. Damico sold 4,000 shares of the company’s stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $50.50, for a total value of $202,000.00. Following the sale, the senior vice president now owns 15,064 shares in the company, valued at approximately $760,732. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP William R. Carapezzi, Jr. sold 32,908 shares of the company’s stock in a transaction dated Thursday, May 12th. The shares were sold at an average price of $50.00, for a total value of $1,645,400.00. Following the completion of the sale, the executive vice president now owns 38,146 shares in the company, valued at approximately $1,907,300. The disclosure for this sale can be found here. 0.05% of the stock is owned by corporate insiders.

PFE traded up $0.59 on Tuesday, reaching $51.26. The stock had a trading volume of 1,133,420 shares, compared to its average volume of 26,819,570. Pfizer Inc. has a fifty-two week low of $38.47 and a fifty-two week high of $61.71. The firm has a 50-day moving average of $51.34 and a 200-day moving average of $52.02. The company has a current ratio of 1.39, a quick ratio of 1.13 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $287.61 billion, a price-to-earnings ratio of 11.78, a price-to-earnings-growth ratio of 0.60 and a beta of 0.76.

Pfizer (NYSE:PFEGet Rating) last issued its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.66 by ($0.04). Pfizer had a return on equity of 38.29% and a net margin of 26.97%. The firm had revenue of $25.66 billion during the quarter, compared to analyst estimates of $24.73 billion. During the same period in the previous year, the company earned $0.93 EPS. Pfizer’s revenue for the quarter was up 76.8% on a year-over-year basis. Sell-side analysts anticipate that Pfizer Inc. will post 6.69 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, June 10th. Shareholders of record on Friday, May 13th will be issued a $0.40 dividend. The ex-dividend date of this dividend is Thursday, May 12th. This represents a $1.60 dividend on an annualized basis and a yield of 3.12%. Pfizer’s payout ratio is presently 36.70%.

PFE has been the subject of several research analyst reports. Morgan Stanley started coverage on Pfizer in a research note on Wednesday, April 6th. They set an “equal weight” rating and a $55.00 target price for the company. StockNews.com upgraded Pfizer from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, April 19th. The Goldman Sachs Group set a $51.00 price target on Pfizer in a research note on Wednesday, May 4th. Barclays set a $52.00 price target on Pfizer in a research note on Tuesday. Finally, JPMorgan Chase & Co. set a $57.00 price target on Pfizer in a research note on Tuesday, May 3rd. Eleven research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $57.05.

Pfizer Profile (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Recommended Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.